Future research comparing the TIL composition in aggressive and non-aggressive BCC and its relation to GATA3 expression is required to understand better GATA3’s role in the BCC TME and BCC response to immunotherapy. The gene discussed is GATA3; the disease is skin basal cell carcinoma.